Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07230353 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv3
  2. Enrollment target: 47 to 68 Study sites: 4 to 3 · Interventions: XmAb13676 (Biological) to Plamotamab (Biological) · Study description revised · 1 morev2 Show 4 more changesShow less
    • Study sites: 4 to 3
    • Interventions: XmAb13676 (Biological) to Plamotamab (Biological)
    • Study description revised
    • Study title expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine the safety and tolerability of plamotamab in patients with rheumatoid arthritis. Participants will be given XmAb13676 subcutaneously (SC) by injection under the skin.
Trial Details
NCT Number NCT07230353
Lead Sponsor Xencor, Inc.
Conditions Rheumatoid Arthritis
Enrollment 68 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov